- Drug Pipelines
- September 2021
- 60 pages
From €2225EUR$2,500USD£1,875GBP
From €3551EUR$3,990USD£2,993GBP
- Report
- October 2021
- 50 pages
€2359EUR$2,650USD£1,988GBP
From €3044EUR$3,420USD£2,565GBP
- Report
- August 2021
- 91 Pages
From €845EUR$949USD£712GBP
- Report
- July 2021
- 628 pages
From €1780EUR$2,000USD£1,500GBP
- Report
- July 2021
- 114 pages
From €3338EUR$3,750USD£2,813GBP
- Clinical Trials
- July 2021
- 60 pages
From €2225EUR$2,500USD£1,875GBP
From €3560EUR$4,000USD£3,000GBP
- Clinical Trials
- May 2021
- 60 pages
From €1335EUR$1,500USD£1,125GBP
From €4450EUR$5,000USD£3,750GBP
- Report
- April 2021
- 50 Pages
From €2314EUR$2,600USD£1,950GBP
From €4984EUR$5,600USD£4,200GBP
- Report
- March 2021
- 48 pages
From €2634EUR$2,960USD£2,220GBP
From €1575EUR$1,770USD£1,328GBP
- Report
- December 2020
- 120 Pages
From €1513EUR$1,700USD£1,275GBP
€1780EUR$2,000USD£1,500GBP
- Drug Pipelines
- November 2020
- 475 pages
From €1780EUR$2,000USD£1,500GBP
- Drug Pipelines
- November 2020
- 1768 pages
From €2225EUR$2,500USD£1,875GBP
- Drug Pipelines
- September 2020
- 386 pages
From €1780EUR$2,000USD£1,500GBP
Cervical cancer is the second most common and the fifth most deadly cancer in women. Approximately 80% of cervical cancers occur in developing countries which makes emerging economies such as China a major target market for pharmaceutical companies in the cervical cancer sector. The following expert reports enable buyers to examine the essential issues: supply and demand, forecasts, drug development and discovery, licensing, SWOT analyses, key industry players and more. This is the place for the inside track on market entry opportunities, growth strategies, buyer solutions and potential industry alliances in the area of cervical cancer drug development. Show Less Read more
